UBS Group’s BeOne Medicines ONC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q3
– Sell
-93,720
Closed -$16.7M – 10075
2023
Q2
$16.7M Buy
+93,720
New +$21.6M 0.01% 1578
2018
Q3
– Sell
-12,500
Closed -$1.92M – 8329
2018
Q2
$1.92M Buy
+12,500
New +$2.23M ﹤0.01% 3216

Other funds holding ONC

UBS Group's ONC Position: Q3 2026 in Review

UBS Group reduced its BeOne Medicines (ONC) stake by 9.7% in Q3 2026, selling an estimated $8.54M and leaving 233,620 shares worth $85.5M. The position accounts for 0.01% of the portfolio, ranked #1220.

UBS Group first reported a position in ONC in Q1 2016 and has held it in 41 quarters since. The position peaked at $123M in Q1 2026. 325 funds tracked by Wall St. Rank hold ONC as of Q3 2026.

  • UBS Group held 233,620 shares of BeOne Medicines worth $85.5M as of Q3 2026.
  • UBS Group sold 24,969 BeOne Medicines shares in Q3 2026, an estimated $8.54M.
  • BeOne Medicines made up 0.01% of UBS Group's portfolio in Q3 2026, its #1220 holding.
  • UBS Group first reported a position in BeOne Medicines in Q1 2016 and has held it in 41 quarters since.
  • UBS Group's BeOne Medicines position peaked at $123M in Q1 2026.
  • 325 funds tracked by Wall St. Rank held BeOne Medicines as of Q3 2026.

Based on UBS Group's 13F filing for Q3 2026, filed 10 Nov 2026.